Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01656174 · ClinicalTrials.gov registry record
Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross
A clinical trial of Dengue, sponsored by Gen-Probe, Incorporated.
- Completed
- Registry status
- 35,035
- Enrollment target
- 2
- Study locations
NCT01656174: Completed study of Dengue, sponsored by Gen-Probe, Incorporated.
NCT01656174 is a study of Dengue that has completed, run by Gen-Probe, Incorporated. The registered enrollment target is 35,035 participants, above the 88-participant average among 9 other Dengue trials with a reported enrollment target (39713% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01656174, a study of Dengue, has completed, sponsored by Gen-Probe, Incorporated.
- COMPLETED
- Registry status
- 35,035 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
Conditions Studied
Interventions
- DEVICE Procleix Dengue Virus Assay
Study Locations (2)
Arizona
- Creative Testing Solutions - Tempe
North Carolina
- American Red Cross National Testing Laboratory - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35,035 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-01 |
What the finished NCT01656174 record still lists
NCT01656174 is an observational study that tracks outcomes without assigning an intervention. Its 35,035 participants enrollment target places it among the larger protocols in the corpus, above the 88-participant average among 9 other Dengue trials with a reported enrollment target (39713% higher).
The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 1 intervention - of which Procleix Dengue Virus Assay is the first listed.
NCT01656174 reports a single indexed study location in Arizona, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01656174 about?
NCT01656174 is a clinical study titled "Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross". The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
What is the current status of trial NCT01656174?
This trial is currently completed. The enrollment target is 35,035 participants. The study started on 2012-08. Estimated completion is 2015-01.
What conditions does trial NCT01656174 study?
This clinical trial studies the following conditions: Dengue.
What interventions are being tested in trial NCT01656174?
The interventions under investigation include: Procleix Dengue Virus Assay (DEVICE).
Who is sponsoring clinical trial NCT01656174?
This trial is sponsored by Gen-Probe, Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01656174 being conducted?
This trial has 2 study locations across Arizona, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dengue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01656174's enrollment target sits among peer trials
35,035 1st of 9 higher than 9 of 9 other Dengue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dengue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
COMPLETED · Phase 1
-
TDENV PIV and LAV Dengue Prime-boost Strategy
COMPLETED · Phase 1
-
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
COMPLETED · Phase 1
-
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
COMPLETED · Phase 1
-
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
COMPLETED · Phase 1
-
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
- NCT03720613 · 34,532 participants
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT07150923 · 36,503 participants · NA
Supraglottic Airway for Resuscitation Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia